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Abstract 
Enterotoxigenic Escherichia coli (ETEC) is the most common cause of diarrhea 
in travellers and young children in developing countries. We previously characterized 
three vaccine candidates (MipA, Skp, and ETEC_2479) which effectively protected mice 
in an intranasal ETEC challenge model after immunization. However, these proteins are 
conserved not only in multiple ETEC isolates, but also in commensal bacteria. In this 
study, we examined the potential of these antigens to affect the host intestinal 
microbiota and subsequently found no significant impact on healthy of host after 
vaccination. In addition, we also optimized the types of adjuvants and forms of antigens 
and evaluated the efficacy in a mouse intranasal challenge model. 
Enterohemorrhagic Escherichia coli (EHEC) is an emerging zoonotic pathogen 
that cause global public health threads. EHEC possesses the potential to cause 
gastroenteritis, hemorrhagic colitis and hemolytic uremic syndrome (HUS), which may 
lead to renal failure. Type  secretion system (T3SS) is a hallmark of EHEC, 
characterized by the needle-like structure and a variety of effectors injected into host 
cells. NleB, one of T3SS effectors, is a glycosyltransferase with the ability to catalyze 
the transfer of N-acetyl-D-glucosamine (N-GlcNAc) to host proteins to suppress the 
activation of NF-B signaling pathway. In this study, we employed luminescence-based 
glycosyltransferase assay and high-throughput screening using a chemical library of 
various compounds. A total of 128 chemicals was selected with significant inhibition on 
NleB glycosyltransferase activity for further pharmaceutical study as novel therapy 
against EHEC infection.  
iv 
 
Table of Contents 
List of Figures vii 
List of Tables viii 
Acknowledgements ix 
Chapter 1 - Literature Review 1 
Escherichia coli and classification 1 
Pathogenesis 3 
ETEC Type  secretion system 3 
EHEC Type  secretion system and effectors 4 
Treatments 6 
ETEC vaccinology 6 
EHEC therapies 7 
Purpose of study 8 
Investigation of Enterotoxigenic Escherichia coli (ETEC) vaccine candidates 8 
Identification of inhibitor of Enterohemorrhagic E. coli (EHEC) type  secretion system 
effector NleB 10 
Chapter 2 - Investigation of Enterotoxigenic Escherichia coli (ETEC) vaccine candidates 14 
Introduction 14 
Materials and Methods 15 
Ethics statement 15 
Antigen purification 15 
Polyclonal antisera production 15 
Immunoassays 16 
v 
 
Fecal DNA extraction 16 
Library construction and sequencing 17 
Informatics analysis 17 
Statistical analyses 18 
Results 19 
Discussion 27 
Chapter 3 - Investigation of Enterotoxigenic Escherichia coli (ETEC) vaccine candidates 29 
Introduction 29 
Materials and Methods 30 
Ethics statement 30 
Antigen purification 30 
Polyclonal antisera production 30 
Immunoassays 31 
Intranasal challenge assays 32 
Results 33 
Discussion 39 
Chapter 4 - Identification of inhibitor of Enterohemorrhagic E. coli (EHEC) type  secretion 
system effector NleB 41 
Introduction 41 
Materials and Methods 42 
Protein purification 42 
N-GlcNAcylation assays 42 
Luminescence assays 43 
Validation screening for NleB inhibitor 43 
Results 45 
vi 
 
Discussion 48 
Reference 50 
 
  
vii 
 
List of Figures 
 
Figure 1 Antigen purification and vaccine mixture with cholera toxin. ............................... 19 
Figure 2 Mice weights during vaccination. ............................................................................. 20 
Figure 3 Vaccination with ETEC MipA, Skp, and ETEC_2479. .......................................... 22 
Figure 4 Sequence diversity among treatment groups. ....................................................... 24 
Figure 5 Principal component analyses and UniFrac distances. ........................................ 26 
Figure 6 Survival curve of intranasal challenge. ................................................................... 34 
Figure 7 Bacterial loads in lung tissues. ................................................................................. 35 
Figure 8 Fecal IgA response. ................................................................................................... 37 
Figure 9 N-GlcNAc Transferase Activity ................................................................................. 46 
Figure 10 Scattergram of percent inhibition ........................................................................... 47 
 
 
 
  
viii 
 
List of Tables 
 
Table 1 NleB orthologs .............................................................................................................. 12 
 
 
  
ix 
 
Acknowledgements 
I would first like to thank my major professor, Dr. Philip Hardwidge for his 
mentorship during these two years. His motivation, patience and wisdom impressed me 
and set a good example of excellent researcher. I have gained and grown a lot with his 
help and support. 
Then I would like to acknowledge my committee members, Dr. T. G. Nagaraja 
and Dr. M M Chengappa for their guidance and suggestion to my program. I would also 
like to thank Dr. Tracy Meisner and other faculty and staff in CVM comparative medicine 
group and in department of Diagnostic Medicine/ Pathobiology. 
My sincere appreciation goes to members in our lab, Michael Hays, Samir 
Elqaidi, Miaomiao Wu, Kangming Chen, Gaochan Wang, and Congrui Zhu for their 
suggestions and assistance. 
Finally, I am grateful to my parents and friends for always supporting and 
encouraging me. 
  
 
 
 
 
1 
 
Chapter 1 -  Literature Review 
Escherichia coli and classification 
Escherichia coli (E. coli) has been extensively studied as the best characterized 
microorganism since its discovery in 1885 by Theodor Escherich. E. coli is capable to 
adapt to proliferate in various environments and lifestyles, not only in gastrointestinal 
(GI) tract and extraintestinal sites of most warm-blood animals. It can also withstand 
harsh environmental conditions outside of hosts for extended period, such as surface of 
plants or in the soil. Typically, E. coli resides in niches of lower intestinal tract of 
mammals, birds, and reptiles as an innocuous commensal bacterium. However, some 
have evolved by improving its robustness and efficient colonization to carry the potential 
to cause diverse diseases in hosts and render challenges to the health of human 
beings. Pathogenic variants of E. coli possess the virulence traits to cause a wide 
spectrum of human diseases ranging from the GI tract such as diarrhea, to 
extraintestinal sites, mostly the bloodstream, urinary tract, and central nervous system1. 
Diarrheagenic E. coli (DEC) is a particular collection of pathotypes involved in diarrheal 
diseases. Although varying significantly in virulence mechanisms, colonization sites and 
clinical symptoms, diarrheagenic E. coli have been traditionally categorized into six 
pathotypes: enterotoxigenic E. coli (ETEC), enterohemorrhagic (Shiga toxin-producing) 
E. coli (EHEC/STEC), enteropathogenic E. coli (EPEC), enteroinvasive E. coli (EIEC), 
diffuse adherent E. coli (DAEC) and enteroaggregative E. coli (EAEC)2. New 
pathotypes, which may have evolved to combine different characteristics, such as a Stx-
producing EAEC strain, are still emerging3. 
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Enterotoxigenic E. coli (ETEC) is the most common cause of diarrhea in 
travellers and farm animals4. The infection of ETEC is typically initiated through intake of 
contaminated water or food. ETEC can persist in contaminated water and adhere firmly 
to surface of fresh vegetables, both increasing the risk of transmission5,6. Two types of 
virulence factors produced by ETEC contribute to its pathogenesis. Adhesins, also 
named colonization factor (CF) antigens including various fimbriae, fibrillae, and 
filamentous protein structures, are expressed to facilitate intestinal colonization by 
binding to specific receptors on host cells7. Once established, ETEC produces 
enterotoxins which consist of heat-labile toxin (LT) and heat-stable toxin (ST), both 
responsible for fluid secretion. LT is arranged as an AB5 where the B subunits mediate 
binding to intestinal cells and the A subunit possesses an ADP-ribosylation activity. LT 
B subunits bind non-covalently to subunit A and attach to enterocytes via ganglioside 
GM1 receptors on the surface8. Activation of adenylate cyclase increases cyclic AMP to 
induce dehydration of enterocytes. LT-B subunit is a potent immunogen and is widely 
considered as a vaccine candidate or adjuvant. While ST is a nonimmunogenic 
polypeptide and responsible for increase of cyclic GMP levels within intestinal cells. As 
a result, chloride secretion is increased, and sodium chloride adsorption is inhibited, 
leading to fluid secretion into lumen of the intestine8. 
Enterohemorrhagic E. coli (EHEC) is an emerging zoonotic pathogen that has 
been the subject of considerable research because of severe public health problem by 
its high morbidity and mortality9. EHEC serotype O157:H7 is capable to cause acute 
gastroenteritis and hemorrhagic colitis in infants and younger children, as well as 
hemolytic uremic syndrome leading to kidney failure and chronic post-infection 
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sequelae. The hallmarks of its pathogenesis are the attaching and effacing (A/E) lesions 
for intimate adherence to host cells and utilization of type  secretion system (T3SS) to 
translocate virulence proteins into infected cell. 
 
Pathogenesis 
ETEC Type  secretion system 
Type  secretion system (T2SS) is used by many Gram-negative bacteria, 
including ETEC, to export diverse proteins across the bacterial membrane to extra-
cellular milieu. Overall, the T2SS is composed of 12 to 15 proteins and assembles as 
three parts: the inner membrane complex providing energy through NTP hydrolysis, the 
pseudopilus which is a pilus-like polymer spanning across the periplasmic compartment, 
as well as a large, pore-forming outer membrane complex responsible for secretion 
specificity10-12. The process of secretion through T2SS is accomplished in two distinct 
steps. The proteins are first oriented by signal peptides to Sec or Tat machinery to 
transport into periplasm from cytoplasm. Then after removal of signal peptides, proteins 
are fully folded for recognition and translocation across the outer membrane to 
extracellular environment13. 
As delivery machinery, aside from exporting fimbrial components, outer 
membrane cytochromes and other surface-associated proteins, T2SS also mediates the 
release of virulence factors, such as LT14. Elucidation of assembly and function of T2SS 
machinery contributes the identification of novel ways to block the delivery of virulence 
factors, which are of great importance in application. For instance, mutation of T2SS, 
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which fails to secrete T2SS associated proteins, is a practical strategy to screen outer 
membrane proteins as potential antigens for vaccine development15.  
EHEC Type  secretion system and effectors 
A/E pathogens, such as EHEC, have evolved an effective delivery system of 
virulence effectors to manipulate host signaling pathway. An important role of the type 
 secretion system is to inject the host cell with a variety of effectors via a needle-like 
structure spanning the inner and outer bacterial membranes. The T3SS consisting of 
more than 30 different proteins is regarded one of the most complicated secretion 
systems16. The hallmark of T3SS structure is composed of three main parts in general: 
extracellular appendages, basal body, and cytoplasmic components17. Extracellular 
appendages consist of translocation pore inserted to the host membrane, needle-
shaped structure protruding above the outer membrane of bacteria, as well as filament 
structure on the top of the needle18,19. Three ring structures spanning the inner and 
outer membrane are connected with a periplasmic inner rod to compose the basal 
body20. The cytoplasmic components contain the C-ring, the ATPase complex, and the 
gatekeeper proteins which serve as sorting platform21,22. The precise assembly and 
regulation of T3SS, ensure the substrates are secreted strictly in proper time. In addition 
to structural proteins, proteins involved in T3SS can be divided into chaperones and 
effectors. The chaperones are some proteins essential for efficient secretion of effectors 
and structural proteins by improving protein stability and recognition23. 
The purpose of effective secretion system assembly is to manipulate the function of 
host cell for bacterial benefit and is fulfilled by injection of various effectors24,25. The 
effectors, as many as 39 in certain EHEC strains16, are classified into two groups, LEE 
5 
 
(locus for enterocyte effacement) encoded and non-LEE effectors (Nle) encoded by 
genetic elements located outside the LEE. Tir is a receptor protein encoded by LEE and 
secreted to the plasma membrane of host cell and acts as a receptor for intimin 
expressed on the surface of bacteria. Binding between Tir and intimin facilitate the tight 
attachment and play an essential role in A/E lesion formation and bacterial 
establishment. Additional non-LEE effectors also contribute to the disruption of host 
signaling and subversion of host innate immune response. For instance, NleB is a 
translocated N-acetyl-D-glucosamine (N-GlcNAc) transferase which mediates N-
GlcNAcylation of mammalian glycolysis enzyme glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) to inhibit its interaction with the TNF receptor associated 
factor 2 (TRAF2) and suppress the activation of downstream NF-B pathway26,27. NleC 
and NleD, which are Zn-dependent proteases, disrupt the host NF-B signaling and AP-
1 activation by inactivation of RelA (p65) and c-Jun N-terminal kinase (JNK) 
pathway28,29. NleE functions as a methyltransferase that binds to TAB2 and TAB3 to 
block the NF-B pathway of host30. NleF was reported to dampen caspase-4-mediated 
inflammatory epithelial cell death and prevent the production of IL-131. NleH1, not 
NleH2, is capable to alter the nuclear translocation of ribosomal protein S3 (RPS3) to 
inhibit NF-B pathway32. The mechanisms of action of T3SS effectors contribution to 
EHEC pathogenesis warrant further investigation. 
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Treatments 
ETEC vaccinology  
ETEC remain leading causes of infantile and traveler’s diarrhea in the developing 
world. Prevention by vaccination is advantageous due to high public health impact, cost-
effectiveness and feasibility of immune protection. Many vaccine developments during 
last decade have largely focus efforts on the best-studied antigens of ETEC, involving 
inactivated whole cell vaccines, live attenuated vaccines and subunit vaccines targeting 
on enterotoxin or surface CFs33,34. However, the vaccines were not efficacious tested in 
clinical trials by the insufficient protections or risk of side effects33,34. Also, the overall 
protection yielded from these vaccines has varied due to the diversity of serotypes from 
ETEC pathovar34. Even more than 25 different CF have been described to be 
antigenically distinct, 40-50 % of ETEC do not produce a recognizable CF36-38. One 
killed whole celll vaccine (Dukoral), which is licensed to prevent cholera, has been 
proved to only provide short-term protection against ETEC due to the high antigenic 
similarity of cholera toxin and LT39. Therefore, to date neither licensed vaccine nor a 
broadly protective vaccine is available40. Currently, studies showed that pathogenesis of 
ETEC is much more complex than previously appreciated and additional virulence 
proteins of surface molecules may be targeted in vaccines15. We have previously 
described three ETEC surface proteins, which were screened out using T2SS mutant, 
as protective antigens. Vaccination with these three proteins (MipA, Skp, and 
ETEC_2479) protected mice in an intranasal challenge15. Further study is still needed to 
select novel vaccine candidates to prevent disease from diverse ETEC. 
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EHEC therapies 
EHEC can cause bloody diarrhea and hemolytic uremic syndrome (HUS) leading 
to acute kidney failure. Recently several devastating EHEC epidemics in Europe have 
urged the need to offer effective therapies41. Current treatment strategy is a 
multitargeted approach. The general supportive treatments, such as fluid and electrolyte 
balance, have been shown to reduce risk of HUS developing42,43. Utilizations of 
antimicrobials, particularly -lactams, are avoided due to the potential risk of endotoxin 
release from dead bacterial cells44. Antibodies targeting lipopolysaccharide (LPS) or A 
subunit of Stx1 have proved to be protective in cell or animal experiment45,46. Even with 
potential of therapeutic use, human trials are still needed to prove clinical effectiveness. 
Artificial probiotics are designed to express proteins to mimic receptors on host cell, so 
as to neutralize the deceived pathogen47. However, these proteins decorated probiotic 
need to survive the adverse condition encountering digestive enzymes and the trial data 
is still awaited. Several vaccine strategies include virulence proteins (Stx1/2), 
recombinant fimbrial proteins, DNA vaccine, live attenuated, or avirulent bacteria48. But 
the immunogenicity varies in different vaccines and the administration modes. 
Moreover, toxin binder such as cell-permeable peptide binds to Stx2 and cause 
increased survival in a baboon model and outcomes of human trials are awaited49. It 
takes time for human trial, but the frequent outbreaks of EHEC, as well as no special 
effective therapy, focus the world’s attention onto development of novel treatments. 
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Purpose of study 
Investigation of Enterotoxigenic Escherichia coli (ETEC) vaccine candidates 
Enterotoxigenic Escherichia coli (ETEC) causes hundreds of millions of cases of 
diarrhea annually, particularly in developing countries50. In addition to their acute impact 
on human health, repeated infections also contribute to delayed growth and 
malnutrition50. Many vaccine strategies have focused on ETEC colonization factors 
(CFs). These heterogeneous surface structures function in attachment by binding to 
host glycoprotein conjugates51. Numerous CFs have been described, but many ETEC 
strains do not produce a recognizable CF34. A need therefore exists to identify new 
vaccine targets that are independent of strain-specific CFs. 
We previously characterized three ETEC H10407 proteins as protective antigens 
in a mouse model involving intranasal bacterial challenge15. Antisera raised against the 
ETEC MipA, Skp, and ETEC_2479 proteins protected HCT-8 cells from attachment by 
multiple ETEC strains15. Immunization with these antigens also protected mice from an 
otherwise lethal challenge with intranasally administered ETEC H1040715. Skp is a 
molecular chaperone that rescues misdirected outer membrane proteins52. MipA is an 
immunoreactive protein that belongs to a family of proteins involved in remodeling 
peptidoglycan53. ETEC_2479 is predicted to function as an outer membrane porin 
involved in long chain fatty acid transport54. The intranasal challenge model is a useful 
alternative for ETEC vaccine studies because mice do not naturally develop diarrheal 
disease after oral ETEC challenge55-57. This model also permits the quantification of 
mouse survival, bacterial clearance, and host immune responses, and stimulates 
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mucosal immune responses, especially secretory IgA (sIgA) responses that are 
important to blocking bacterial adherence to mucosal surfaces. 
Identifying broadly conserved, protective antigens is important to vaccine 
development. However, MipA, Skp, and ETEC_2479 are conserved not only among 
pathogenic ETEC strains, but also among the commensal Proteobacteria. This may be 
an important issue because it is known that alteration of commensals can influence 
susceptibility to gastrointestinal disease and vaccine efficacy58,59. Several previous 
studies have begun to address this issue. Rotavirus vaccination of humans did not have 
a major impact to infant microbiomes60. A challenge of cynomolgus macaques with an 
oral-live attenuated Shigella strain found a possible protective role for the microbiota 
and highlighted the importance of considering host genetics in vaccine studies61. Oral 
immunization with the live-attenuated typhoid vaccine strain Ty21a did not cause 
significant perturbation of the fecal microbiota related to vaccine administration62. Thus, 
while the impact of inactivated viral vaccines and live-attenuated bacterial vaccines on 
the host microbiota have been examined, the potential impact of using subunit vaccines 
consisting of antigens that are also encoded by commensal organisms has not been 
investigated. 
In addition, our previous work used GST-tagged forms of MipA, Skp, and 
ETEC_2479 to demonstrate vaccine efficacy, but an antigen lacking the epitope 
purification tags will be appropriate for further study. Although cholera toxin (CT) is an 
effective adjuvant, it is not suitable for future vaccine trials due to its enterotoxicity. So 
we employed a novel vaccine strategy based on outer membrane vesicles (OMVs). 
OMVs are released by both pathogenic and non-pathogenic Gram-negative bacteria 
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which is a ubiquitous process during normal growth63,64. The artificial presentation of 
target antigens in complex with the natural presence of LPS as an adjuvant makes 
OMVs an effective means to induce host immune response65-67. 
We hypothesized that using the conserved antigens MipA, Skp, and ETEC_2479 
as subunit vaccine candidates could negatively impact the health of the host by 
affecting the intestinal microbiota. We also assumed that both untagged vaccine 
candidates and employment of OMVs could yield effective protection in mice challenge 
model. Herein, we tested and subsequently failed to reject these hypotheses. 
Identification of inhibitor of Enterohemorrhagic E. coli (EHEC) type  secretion 
system effector NleB 
Enterohemorrhagic E. coli (EHEC) have been a major cause of gastroenteritis 
and hemorrhagic colitis as well as hemolytic uremic syndrome (HUS), which present 
great challenges to public health. They carry an enormous potential to cause acute 
renal failure which is detrimental to human health. However, no special effective therapy 
exists to date, giving motivation to develop a promising medication with protective 
efficacy. 
EHEC is distinctively characterized by the attaching and effacing (A/E) lesions for 
intimate adherence to host cells and utilization of type  secretion system (T3SS) to 
translocate virulence proteins into infected cell. A plethora of effector proteins are 
injected by T3SS to modulate the innate immune system via several different 
mechanisms. T3SS effector NleB is described to be highly conserved among A/E 
pathogens enterohemorrhagic E. coli (EHEC), enteropathogenic E. coli (EPEC), and 
Citrobacter rodentium, which is a mouse pathogen using similar strategies with E. coli68. 
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EHEC carries two copies of NleB, NleB1 and NleB2, which are encoded in separate 
pathogenicity islands. NleB1 and NleB2 are highly related and share 60 to 62 % amino 
acid identity and ~80 % similarity. NleB1 from EHEC and EPEC share ~98 % amino 
acid identity with each other and have ~89 % amino acid identity and ~96 % similarity 
with NleB of C. rodentium which is its only copy. In addition, Salmonella enterica strains 
also possess three NleB orthologs, SseK1, SseK2, SseK369. NleB is a bacterial 
glycosyltransferase with the ability to modify the arginine residues by translocating N-
acetyl-D-glucosamine (N-GlcNAc), which is an atypical post-translational modification 
(PTM) not observed in eukaryotic cells. Glycosylation of the mammalian glycolysis 
enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) by NleB disrupts its 
interaction with TNF receptor associated factor 2 (TRAF2) and subsequently suppress 
TRAF2 polyubiquitination and NF-B activation27. Other host proteins which are 
substrates of NleB orthologs have been reported, such as Fas-associated via death 
domain (FADD), TNFRSF1A-associated via death domain (TRADD), and receptor-
interacting serine/threonine kinase 1 (RIPK1)70. However, the preferences of substrate 
in different NleB orthologs vary and mechanisms are still under investigation (detail in 
Table1)71-74. NleB is also essential for virulence of C. rodentium in mice. NleB deficient 
C. rodentium strains exhibited attenuated ability to colonize in mice model27. NleB is 
exemplified as a virulence strategy how pathogens employ T3SS and its effectors to 
inhibit NF-B dependent host innate immune responses. 
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Table 1 NleB orthologs 
NleB ortholog 
Effect on NF-B 
pathway 
substrate 
GAPDH FADD TRADD RIPK1 
EHEC NleB1 block yes Yes * * 
EHEC NleB2 -- no No * * 
EPEC NleB1 block no Yes yes yes 
EPEC NleB2 -- no No * * 
C. rodentium NleB block yes Yes * * 
S. enterica SseK1 block yes Yes/no yes * 
S. enterica SseK2 -- no Yes * * 
S. enterica SseK3 block no No yes * 
Table1: the preference substrate of NleB orthologs. EHEC= enterohemorrhagic E. coli: 
EPEC= enteropathogenic E. coli: block=inhibit the activity; yes= substrate; no=not 
substrate; yes/no= conflicting reports; *= not tested. 
Although EHEC cause severe outbreaks and present tremendous challenge to 
public health, no practical and effective therapy is available to date and research efforts 
are still needed48. Recently, some studies on toxin inhibitor or binder have shed light on 
investigation of potential therapy. For instance, a novel agent can bind to Stx directly as 
a neutralizer and inhibit its binding to receptor presented on target cells75. Another study 
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use cell-permeable peptide as a toxin binder to neutralize Stx2 and increase survival in 
a baboon model49. So in this study, we employed a luminescence-based 
glycosyltransferase assay to screen a potential inhibitor of NleB which contribute to 
EHEC pathogenesis. The UDP-GloTM glycosyltransferase assay is a bioluminescent 
assay to determine the activity of UDP-GlcNAc glycosyltransferase. The released UDP 
from UDP-sugar in glycosyltransferase reaction is then converted to ATP and measured 
by light intensity using a luminometer. After using a variety of chemical compound in 
reaction, the inhibitor candidate can be screened out by significantly reduced 
luminescence. The potential inhibitors of NleB are worthy of further investigation as a 
novel therapeutic modality against EHEC infection. 
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Chapter 2 -  Investigation of Enterotoxigenic 
Escherichia coli (ETEC) vaccine candidates 
These data were published in 201535. 
Introduction 
Enterotoxigenic Escherichia coli (ETEC) is the leading cause of diarrhea of 
young children in developing countries and adults and children traveling to endemic 
areas50. Antigenic and structural heterogeneity among colonization factors of ETEC 
pathovar has complicated vaccine development efforts. Identifying and characterizing 
conserved ETEC antigens that induce broadly protective immunity is therefore of 
interest. We previously characterized three proteins (MipA, Skp, and ETEC_2479) that 
protected mice in an intranasal ETEC challenge model after vaccination15. However, 
these proteins are conserved not only in multiple ETEC isolates, but also in commensal 
bacteria. While the impact of inactivated viral vaccines and live-attenuated bacterial 
vaccines on the host microbiota have been examined, the potential impact of using 
subunit vaccines consisting of antigens that are also encoded by commensal organisms 
has not been investigated. We addressed this issue by characterizing changes to 
mouse intestinal microbiomes as a function of vaccination. We hypothesized that using 
the conserved antigens MipA, Skp, and ETEC_2479 as subunit vaccine candidates 
could negatively impact the health of the host by affecting the intestinal microbiota. 
Herein, we tested and subsequently refuted this hypothesis. 
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Materials and Methods 
Ethics statement 
Animal experiments were performed according to Kansas State University 
Institutional Animal Care and Use Committee-approved protocols (IACUC #3648). This 
institution complies with all applicable provisions of the Animal Welfare Act and other 
Federal statutes and regulations relating to animals. 
Antigen purification 
Escherichia coli BL21 (DE3) strains expressing individual antigens were grown 
overnight as described15. A single colony of each expressing strains was cultured in 4 
ml Luria-Bertani (LB) broth supplemented with 50 µg/ml Kanamycin shaking at 37 °C 
overnight. 2 ml of the overnight culture was transferred to 200 ml LB medium containing 
50 µg/ml Kanamycin. Once optical density (OD) value of the culture reached 0.4~ 0.6, I 
mM Isopropyl β-D-1-thiogalactopyranoside (IPTG; Sigma, MO) was added to into 
culture to induce protein expression for 5 h shaking at 37 °C. Culture were collected and 
proteins were purified by using nickel-affinity chromatography. After purification, 
proteins were dialyzed into glycerol in Pierce Slide-A-Lyzer dialysis cassettes. Protein 
concentrations were quantified by using the Precision Red Advanced Protein Assay 
(Cytoskeleton, Inc.). 
Polyclonal antisera production 
Female BALB/c mice of matched age (6 weeks at initial vaccination) were 
obtained from the Jackson Laboratory (Bar Harbor, Maine) and handled as described 
previously15. Mice were housed (5 per group) in microisolator cages (1 cage per group) 
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and provided with food and water ad libitum. Antigens (20 µg/dose) were mixed with 2.5 
µg of cholera toxin in 25 µl phosphate-buffered saline (PBS) and then administered 
intranasally to the external nares of mice that had been anesthetized with isoflurane15. 
Two booster doses were administered, at 2- and 4-weeks after the initial vaccination. 
Mice were euthanized 2 weeks after the final immunization and exsanguinated. The 
blood was processed into serum using centrifugation for 2 min at 2500g in a BD 
microcontainer serum separator tube. Control serum samples were also obtained from 
mice immunized with PBS or with EHEC EspB. 
Immunoassays 
Enzyme-linked immunosorbent assays (ELISAs) were performed as previously 
described15, using serial dilutions of mouse serum samples and polystyrene 96-well, flat 
bottom plates (Whatman) coated with purified antigens or with bovine serum albumin 
(BSA; 0.5 µg/ml). Plates were developed with 1-StepTM Ultra TMB-ELISA (Thermo) 
and quenched with 3 N H2SO4. Absorbance was read at 450 nm. 
Fecal DNA extraction 
A fecal pellet from each mouse was collected weekly, with the initial collection 
prior to the first vaccination and the final collection 2 weeks after the final vaccination. 
After collection, the fecal pellets were stored at −80 °C until DNA extraction could be 
performed. Prior to DNA extraction using QIAamp DNA Stool Mini Kits (Qiagen), 1.4 ml 
of Buffer ASL was added to fecal samples on ice. Fecal pellets were vortexed until 
completely resuspended and DNA was extracted by following the manufacturer’s 
protocol. 
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Library construction and sequencing 
Library construction and sequencing was performed essentially as described76. 
Prior to PCR, DNA concentrations were determined via fluorometry (Qubit dsDNA BR 
assay, Life Technologies, Carlsbad, CA) and normalized to a standard concentration. 
Bacterial Microbial 16S rRNA amplicons were generated via amplification of the V4 
hypervariable region of the 16S rRNA gene using single-indexed universal primers as 
described previously [U515F/806R; 77] flanked by Illumina standard adapter sequences. 
Primer sequences are available at proBase [78; http://www.microbial-
ecology.net/probebase/]. PCR was performed using the following parameters: 98 °C(3:00) 
+ [98 °C(0:15) + 50 °C(0:30) + 72 °C(0:30)] × 25 cycles +72 °C(7:00). Following PCR, 
amplicons were pooled for sequencing using the Illumina MiSeq platform and V2 
chemistry with 2 × 250 bp paired-end reads. 
Informatics analysis 
Informatics analysis was performed essentially as described76. FLASH software 
was used to assemble contiguous DNA sequences78. Sequences were culled if 
determined to be short after trimming for a base quality less than 31. Reference-based 
and de novo chimera detection and removal was conducted using Qiime v1.8 
software79. Remaining contiguous sequences were assigned to operational taxonomic 
units (OTUs) via de novo clustering with a criterion of 97 % nucleotide identity as 
described76. Annotation of selected OTUs was performed using BLAST 80 against the 
Greengenes database81 of 16S rRNA sequences and taxonomy. Principal component 
analysis was performed using ¼ root-transformed OTU relative abundance data via a 
non-linear iterative partial least squares (NIPALS) algorithm, implemented using an 
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open access Excel macro available from the Riken Institute 
(http://prime.psc.riken.jp/Metabolomics_Software/StatisticalAnalysisOnMicrosoftExcel/in
dex.html). Sequence data were deposited in the NCBI Sequence Read Archive (SRA) 
under the BioProjectID PRJNA320839. 
Statistical analyses 
Statistical analysis was performed using Sigma Plot 12.3 (Systat Software Inc., 
Carlsbad, CA). Interactions and differences between treatment groups and time-points 
in Chao1 indices were determined using 2-way analysis of variance (ANOVA). Analysis 
of molecular variance (AMOVA) was implemented in a general linear model using SPSS 
software, version 23 (IBM, Armonk, NY). Results were considered statistically significant 
for p values ≤0.05. 
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Results 
 Mice were vaccinated intranasally with purified, recombinant forms of ETEC 
MipA, Skp, and ETEC_247915, as well as with a purified, recombinant form of E. coli 
O157:H7 EDL933 EspB (Fig. 1)82. EspB was used as an external control because it is 
immunogenic but is not expressed by either ETEC or by commensal bacteria83. 
Figure 1 Antigen purification and vaccine mixture with cholera toxin. 
 
Coomassie stained SDS-PAGE gel of vaccine mixtures. Lane legends are 1, protein marker; 2, 
purified Skp protein and cholera toxin; 3, purified MipA protein and cholera toxin; 4, purified 
ETEC_2479 protein and cholera toxin; 5, purified EspB protein and cholera toxin; and 6, cholera 
toxin control. 
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Mouse health and weight gain were monitored during the vaccination regimen. 
Neither obvious changes to mouse health or behavior, nor changes in the rate of weight 
gain were observed. The weights of the mice after vaccination were 21.1 ± 1.0 g for the 
PBS control group, 20.7 ± 1.0 g for EspB, 21.2 ± 0.9 g for MipA, 21.2 ± 2.0 g for Skp, 
and 21.3 ± 0.9 g for ETEC_2479 (p > 0.05) (Fig. 2). After 3 immunizations, mice were 
sacrificed and their serum was used in ELISAs to quantify antibody titers. All mice 
(5/group) produced detectable IgG titers (Fig. 3a). Fecal IgA responses for mice 
immunized with either MipA, Skp, or ETEC_2479 ranged from a 13.2 ± 2.2, 13.0 ± 3.4, 
and 26.8 ± 4.6 fold-increase as compared with control groups, respectively15.  
Figure 2 Mice weights during vaccination. 
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Mice weights during vaccination. Skp1-5: Five mice immunized with Skp+CT; MipA1-5: Five 
mice immunized with MipA+CT; ETEC_24791-5: Five mice immunized with ETEC_2479+CT; 
EspB1-5: Five mice immunized with EspB+CT; PBS1-5: Five mice immunized with PBS+CT. 
To determine whether vaccination affected the diversity and overall composition 
of the mouse intestinal microbiota, 16S rRNA amplicon sequencing was performed 
using DNA extracted from feces collected prior to vaccination, from the mid-point of the 
vaccination regimen (after the second vaccination), and two weeks after the final 
vaccination, as template. Following vaccination, there were no apparent differences in 
the microbial profiles when resolved to the level of operational taxonomic unit (OTU), 
and the same six OTUs (families S24-7, Lachnospiraceae, Ruminococcaceae, order 
Clostridiales, Oscillospira sp., and Anaeroplasma sp.) dominated the pre- and post-
vaccination microbiota of all groups (Fig. 3b). Regarding the effect of vaccination on 
other Gram-negative taxa that potentially express the targeted antigens, i.e., microbes 
in the order Bacteroidales or phylum Proteobacteria, no differences were detected 
between pre- and post-vaccination samples in the relative abundance of these bacteria 
(Fig. 3c). The Chao1 index, a measure of α-diversity (i.e., within samples), was also 
compared between groups to determine if vaccination affected the richness or 
distribution of microbes. Two-way ANOVA detected no significant differences between 
groups, or between pre- and post-vaccination samples (Fig. 4a). Samples obtained from 
the mid-point of the vaccination regimen (after the second vaccination) were also 
analyzed and were not significantly different from pre-or post-vaccination samples (Fig. 
4a). Similarly, neither the Shannon diversity index, nor the raw number of unique 
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sequences detected in each group, were significantly different among groups (Fig. 4b, 
c). 
Figure 3 Vaccination with ETEC MipA, Skp, and ETEC_2479. 
 
Vaccination with ETEC MipA, Skp, and ETEC_2479. a Serum IgG responses in mice. Data are 
plotted as the fold-change in serum IgG after immunization with the indicated antigens, n = 
5/group. b Bar chart showing relative abundance of all operational taxonomic units (OTUs) 
detected in the feces of mice prior to (pre) and 6 weeks after (post) vaccination with the 
indicated antigens, as detected using 16S rRNA amplicon sequencing. The identities of 
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dominant taxa are shown at the right. c Mean number + standard deviation (SD) of sequence 
reads that were specific to Bacteriodales or Proteobacteria in indicated treatment groups. 
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Figure 4 Sequence diversity among treatment groups. 
 
25 
 
Sequence diversity among treatment groups. a Bar chart showing mean + standard deviation 
(SD) Chao1 a-diversity index of fecal microbiota in mice pre- and post-vaccination with the 
indicated antigens, as detected using 16S rRNA amplicon sequencing. b Mean Shannon 
diversity indices. c Mean number of unique sequences in treatment groups. 
 
Principal component analysis (PCA) was performed both to assess β-diversity 
(i.e., between samples) and to determine if vaccination induced changes in the overall 
composition of the microbiota. No clustering of post-vaccination samples was observed 
in plots of principal component 1 (PC1) against PC2 or PC3, which accounted 
collectively for over 60 % of the variability between samples, suggesting that there were 
negligible shifts in the bacterial community composition of any treatment group (Fig.5a). 
A comparison of the mean intragroup unweighted UniFrac distance between pre- and 
post-vaccination samples detected no greater dissimilarity between the two samples in 
treated groups as compared to the control group, as determined by performing ANOVA 
with post hoc Dunnett’s tests (Fig. 5b). Supporting our prior analysis, AMOVA detected 
no significant effect of vaccination treatment (p = 0.053; F value = 3.302), and also no 
significant effect of time-point (p = 0.359; F value = 4.517), using the first and last 
samples as time-points. 
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Figure 5 Principal component analyses and UniFrac distances. 
 
Principal component analyses and UniFrac distances. a Unweighted principal component 
analyses showing β-diversity of fecal microbiota in mice pre- and post-vaccination with the 
indicated antigens, as detected via 16S rRNA amplicon sequencing. Principal component 1 
(PC1) versus PC2 (left) and PC1 versus PC3 (right) are shown. Color-coding is identical to Fig. 
4, with open symbols representing pre-vaccination and closed symbols representing post-
vaccination samples. b Mean intragroup unweighted UniFrac distances between pre- and post-
vaccination samples. 
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Discussion 
The discovery and characterization of broadly conserved ETEC vaccine antigens 
that are independent of strain-specific CFs is of emerging interest. However, an 
important consideration is whether targeting antigens also expressed by commensal 
flora will negatively impact host health or vaccine efficacy. We have characterized the 
ETEC proteins MipA, Skp, and ETEC_2479 for their protective efficacy in an intranasal 
challenge model. These proteins are highly conserved not only in diverse ETEC 
isolates, but also in commensal Proteobacteria and other E. coli and Shigella strains, 
sharing ~99 % identity with the corresponding Shigella proteins. Because altering 
commensal abundance and diversity may affect host health and vaccine efficacy, we 
were therefore interested in determining whether using these antigens in a subunit 
vaccine would affect the mouse microbiota. Commensal E. coli strains may contribute to 
colonization resistance against pathogens84. For example, E. coli Nissle 1917 has been 
extensively characterized as a probiotic agent85 and could potentially function by 
competing for nutrients that are required by pathogens84. They also play important, 
though incompletely defined roles in maintaining intestinal homeostasis86. 
We did not observe changes to mouse health, behavior, or rate of weight gain 
following intranasal vaccination with either MipA, Skp, or ETEC_2479. We also 
observed no significant differences among the microbial profiles when resolved to the 
level of operational taxonomic unit (OTU), as determined by performing 16S rRNA 
amplicon sequencing. Analysis of the Chao1 index, the Shannon diversity index, and 
the raw number of unique sequences detected in each treatment group, also failed to 
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reveal any significant differences. PCA analysis and comparison of UniFrac distances 
also suggested negligible shifts in the bacterial community composition of any treatment 
group. 
While no consistent shifts in the composition of the fecal microbiota were 
detected following vaccination against the three conserved candidate antigens, a closer 
examination of the effects of vaccination on the relative abundance of taxa expected to 
express these antigens, i.e., bacteria within order Bacteroidales and phylum 
Proteobacteria, was performed. While no vaccination-dependent differences were 
detected in the relative abundance of these groups, we recognize that both 
Bacteroidales and Proteobacteria are rare taxa in the current samples. This is not 
however unique to this cohort of mice, as we have demonstrated very comparable 
levels of these taxa in multiple genetic backgrounds of mice purchased from the same 
vendor and the overwhelming majority of gut bacteria in most research mice are Gram-
positive87. Regardless, the low numbers of Gram-negative bacteria present in the 
present cohorts were not affected by vaccination. It will be important in future studies to 
validate these studies using diarrheal disease models for ETEC in either mice or piglets. 
Overall, despite the conservation of MipA, Skp, and ETEC_2479 among Gram-
negative bacteria, vaccination with these antigens fails to alter significantly the host 
intestinal microbiota and suggests that their inclusion in future ETEC vaccine 
preparations may be efficacious. 
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Chapter 3 -  Investigation of Enterotoxigenic 
Escherichia coli (ETEC) vaccine candidates 
Introduction 
Enterotoxigenic E. coli (ETEC) is a leading cause of diarrhea in travelers and 
farm animals50. Vaccines have been considered as an efficacious way to prevent ETEC 
infection. Typically, vaccines targeting on surface antigens on bacteria can yield 
effective protection by inducing immune response. However, the antigenic and 
structural heterogeneity among various ETEC pathovar has posed a great challenge to 
vaccine development efforts. In our previous study, three proteins (MipA, Skp, and 
ETEC_2479) were identified and characterized as vaccine candidates due to the ability 
to protect mice in an intranasal ETEC challenge model after vaccination15. In addition to 
antigens, adjuvants also play essential role in induction of immune response. Delivery of 
antigens via outer membrane vesicles (OMVs) is a novel and effective means due to the 
artificial presentation of antigens in complex with the natural presence of LPS as an 
adjuvant. In this study, we employed OMV for antigen presentation and adjuvantation 
and then evaluated the protection from OMV delivered antigens in a mouse pulmonary 
challenge model. We also refined the vaccine candidates in the absence of cholera 
toxin (CT) and epitope purification tags to investigate the impact of adjuvants and 
epitope tags of antigens on vaccine efficacy for potential clinical trial. 
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Materials and Methods 
Ethics statement 
Animal experiments were performed according to Kansas State University 
Institutional Animal Care and Use Committee-approved protocols (IACUC #3900). This 
institution complies with all applicable provisions of the Animal Welfare Act and other 
Federal statutes and regulations relating to animals. 
Antigen purification 
Escherichia coli BL21 (DE3) strains expressing individual antigens were grown 
overnight as described15. A single colony of each expressing strains was cultured in 4 
ml Luria-Bertani (LB) broth supplemented with 50 µg/ml Kanamycin shaking at 37 °C 
overnight. 2 ml of the overnight culture was transferred to 200 ml LB medium containing 
50 µg/ml Kanamycin. Once optical density (OD) value of the culture reached 0.4~ 0.6, I 
mM Isopropyl β-D-1-thiogalactopyranoside (IPTG; Sigma, MO) was added into culture 
to induce protein expression for 5 h shaking at 37 °C. Cultures were collected and 
proteins were purified by using nickel-affinity chromatography. After purification, 
proteins were dialyzed into 10 % glycerol in Pierce Slide-A-Lyzer dialysis cassettes. N-
terminal epitope tag were removed by TEV protease if necessary. Protein 
concentrations were quantified by using the Precision Red Advanced Protein Assay 
(Cytoskeleton, Inc.). 
Polyclonal antisera production 
56 BALB/c female mice of matched age (3-4 weeks of age) were obtained from 
Jackson Laboratory and divided randomly into 14 groups of 4 mice. The mice were 
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housed in microisolator cages and provided with food and water ad libitum. Individual 
proteins (20 µg) will be combined with 2.5 µg cholera toxin (CT) and mixed in sterile 
phosphate-buffered saline (PBS) to a final volume of 25 µl. OMVs were obtained from 
Abera Bioscience and are purified from S. enterica serovar Typhimurium at a 
concentration of 8 optical density 660 nm (OD660) equivalents per 5 µl. Inoculum of 
purified proteins (25 µl) or OMVs (5 µl) or PBS (25 µl) will be administered intranasally 
to the external nares of mice that have been lightly anesthetized with isoflurane. Two 
identical booster doses will be administered 2- and 4-weeks subsequent to the initial 
vaccination. Fecal samples were collected before the immunization and challenge 
respectively to monitor the production of mucosal antibody. Fresh stool pellets (5-6 
pellets) of each mice were collected and added to 1 ml of fecal reconstitution buffer. The 
fecal reconstitution buffer includes 50 mM ethylenediaminetetraacetic acid (EDTA), 0.1 
mg/ml soybean trypsin inhibitor, 1.39 μg/ml phenylmethylsulfonylfluoride (PMSF) and 
homogenized. The fecal samples were homogenized thoroughly and centrifuged (5 min, 
5,000 g) to remove insoluble material. The supernatants were stored at -4 °C. 
Immunoassays 
IgA concentrations in mouse feces were quantified and analyzed by Enzyme-
Linked Immunosorbent Assay (ELISA). ELISAs were performed in polystyrene 96-well, 
flat bottom plates (Whatman) which were coated with 0.5 μg/ml of each purified protein 
or bovine serum albumin (BSA) and incubated overnight 4 °C. Plates were washed 3X 
in PBST (PBS with 0.1 % Tween-20) and blocked with 5 % milk in PBS, 0.1 % Tween-
20 for 1 h at room temperature. After wash 3X with PBS, plates were inoculated with 50 
μl of supernatant from each fecal sample in triplicate at 4 °C overnight. Rabbit anti-
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mouse IgA HRP detection antibody (Sigma) was diluted 1:4,000 in PBST and added to 
the well to incubate at 37 °C for 1 h. Plates were developed with 1-StepTM Ultra TMB-
ELISA (Thermo) following the manufacturer’protocol and quenched with 3 N H2SO4. 
Absorbance was read at 450 nm to quantify the antibody titers. For statistical test, 
antibody titers were first transformed logarithmically and the Student’s t test was 
employed to compare the average antibody titer values of different groups of mice with 
those of non-immunized mice. Any difference in P values of < 0.05 was considered 
significant. 
Intranasal challenge assays 
Two weeks after the final immunization, mice were lightly anesthetized with 
isoflurane in a VetEquip RC2 isoflurane and challenged intranasally with 5x108 CFUs of 
ETEC H10407 which were cultivated on Colonization Factor Antigen (CFA) agar at 37 
˚C for 18 h. The mice were observed every 8 h after challenge. Changes to mouse 
clinical signs of illness were quantified and recorded as a function of ETEC challenge 
and immunization. Clinical signs of illness were categorized into lack of responsiveness 
to stimulation, hunched posture, ruffled hair coat, dehydration. Mice with any clinical 
signs of illness or at the end of the study (7 d) were euthanized, necropsied. Data were 
analyzed statistically using log-rank tests. The lungs were extracted aseptically and 
dissected into halves. One half of each lung was homogenized for quantification of 
ETEC colonies. Serial dilutions of lung homogenates were prepared and plated on 
MacConkey agar (MAC) for quantification of ETEC concentrations. The other half of the 
left lung was immersed in formalin for subsequent histopathology studies. The other half 
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of the right lung was flash frozen in liquid nitrogen and stored at -80 ˚C for subsequent 
biochemical assays. 
Results 
Three ETEC H1047 proteins were previously characterized as protective 
antigens in a mouse model with intranasal challenge15. In this study, the impacts of 
OMV delivery of antigens as well as purification epitope tag of proteins on the vaccine 
efficacy are of interest. We employed a well-developed hemoglobin protease (Hbp) 
autotransporter platform for presentation of heterologous polypeptides on the surface of 
Salmonella OMVs. Antigens without epitope tags were obtained using TEV protease 
and nickel-affinity chromatography to eliminate cleaved epitope tags. Antigens 
regardless of the presence of epitope tags were immunized with cholera toxin (CT) 
which serves as a potent adjuvant. While OMVs display of antigens processes the 
ability to induce immune response with the nature presentation of LPS as an adjuvant. 
To investigate whether the EHEC antigens (MipA, Skp, and ETEC_2479) with absence 
or presence of epitope tag and OMVs have any difference in protection from EHEC 
infection, we adapted an established intranasal mouse challenge model. The mice were 
divided into 14 groups (4 mice/group) and immunized three times at two-week intervals 
with antigens combined with or without OMVs. Two weeks after the final immunization, 
mice were challenged intranasally with 5x108 CFUs of ETEC H10407, which has been 
cultivated on Colonization Factor Antigen (CFA) agar to facilitate the expression of 
colonization factors. Clinical signs were observed every 8h over a 7-day period and 
evaluated as a criteria of protected or not. Compared with the mice immunized with PBS 
or OMV without packaging antigens, which did not survive longer than 72 h after 
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infection, all antigen combinations were protective against the infectious challenge to 
variable degrees (Fig. 6). All mice immunized with three antigens containing epitope 
tags survived after 7 days, which is similar to our previous study15. OMVs delivery of 
both Skp fragment 1 and fragment 2, as well as MipA in absence of epitope tags also 
provided remarkable protection to survive the infection. Another OMVs presentation of 
three antigens, which were Skp fragment 1, Skp fragment 2 and MipA combined with 
Skp, yielded significant degrees of protection with 75 % survival of the mice. In contrast, 
OMVs delivery of MipA, untagged Skp and untagged ETEC_2479 were less effective 
with only 50 % protection of immunized mice. 
 
Figure 6 Survival curve of intranasal challenge. 
 
Survival curve of intranasal challenge. Mice were challenged with ETEC H10407 after 
immunization with the indicated antigens. The survival of mice is plotted as a function of time. 
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Bacterial Loads of lung tissues were quantified after euthanization and 
dissection. ETEC loads were related to the survival of mice (Fig. 7). Significantly high 
loads of ETEC, which were about ~106−10 CFUs/g, were cultured from lungs of mice that 
didn’t survive the infection. Whereas, bacterial loads were relatively lower in lungs of 
surviving mice, all less than ~106 CFUs/g. 
 
Figure 7 Bacterial loads in lung tissues. 
 
Bacterial load in lung tissues of mice inoculated with 5 × 108 CFU of ETEC H10407. After 
euthanization, half of lung tissues were collected and homogenized. Serial dilutions were placed 
on MacConkey agars. Colony-forming units (CFU) were determined 24 h after plating and were 
expressed as log CFU. Individual animals are represented by individual symbols. Open symbols 
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indicate mice that survived for the duration of the study. Closed symbols indicate mice that were 
euthanized due to their display of clinical signs of illness. 
Fecal IgA response against different antigens evaluated using ELISA were more 
variable but highly correlated to mouse survival and inversely related to the ETEC loads 
(Fig. 8). No effective IgA response was detected in mice immunized with PBS or OMVs 
without antigens. MipA without OMVs regardless of the presence of epitope tags have 
the highest fecal IgA response to MipA (Fig. 8a). Three mice in OMV-Skp-MipA group 
and two mice in both OMV-MipA and OMV-SkpMipA+2479 yield significantly higher IgA 
response (more than 10-fold). In contrast, IgA responses against Skp were more 
variable also with the most effective response in tagged Skp group (Fig. 8b). Only 2 
mice in untagged Skp and also in OMV-SkpMipA+2479 developed IgA response more 
than 10 folds. But mice in groups of other antigen combination has at least 3 mice with 
IgA response more than 10 folds. However, ETEC_2479, which failed to be packaged 
into OMV platforms, yield relatively lower IgA response (Fig. 8c). Even in tagged 
ETEC_2479 antigen group, all mice were effectively protected but still with lower IgA 
compared to tagged MipA and Skp. 2 mice in untagged ETEC_2479 antigen group and 
only 1 mice in OMV-SkpMipA+2479 group were able to produce effective response 
(more than 10-fold). 
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Figure 8 Fecal IgA response. 
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Fecal IgA responses in mice. Data are plotted as the fold-change in fecal IgA against MipA(a), 
Skp (b), or ETEC_2479 (c) after immunization with the indicated antigens, n = 5/group. Open 
symbols indicate mice that survived for the duration of the study. Closed symbols indicate mice 
that were euthanized due to their display of clinical signs of illness. 
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Discussion 
Enterotoxigenic E. coli (ETEC) causes diarrhea in traveler and farm animals in 
developing countries. Developments of efficacious vaccines against ETEC infection are 
of interest. We have identified three surface proteins (MipA, Skp, and ETEC_2479) as 
vaccine candidates due to their effective protection from ETEC infection in an intranasal 
mouse challenge model. Outer membrane vesicles (OMVs) shedding from Gram-
negative bacteria are used in vaccine development due to its ability to carry 
heterologous antigens and natural presentation of LPS as adjuvant88. In this study, 
ETEC antigens (MipA, Skp) were targeted to the surface of Salmonella OMVs after 
fusion to hemoglobin protease (Hbp). However, the efficacy of OMVs vaccine is less 
than expected compared to the traditional combination of antigens and adjuvants. Some 
potential reasons may lead to these results. The antigen concentration in OMVs is less 
than the traditional antigens. These protein antigens are sensitive to the protease 
digestion in the host respiratory mucosa. So excessive amount of antigens were used 
for immunization89. While antigens presented on surface of OMVs still have the same 
risk of being degraded due to absence of surface protective structure, such as pilus64. 
Despite antigens are more concentrated carried by OMVs, the total amount of antigens 
per dose is much less than the excessive amount of antigens alone. So the effective 
antigens which succeed to approach the host cell and induce immune response are less 
in OMV vaccines. To optimize, instead of display on surface, package of antigens in 
lumen of OMVs has potentially better protection of antigens and can be incorporated 
into future vaccine designs90. In addition, other OMV-enriched proteins, such as 
autotransporters, regulatory proteins involved in iron and zinc acquisition, and two-
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partner secretion systems, which are selectively packaged into OMVs, may be a better 
candidate to fuse heterogeneous antigens64,91,92. 
 In addition, our study showed the antigens with epitope tags have better 
performance on induction of immune response and protection of infectious mice than 
antigens in absence of epitope tags. This indicates that the purification epitope tags, 
which are His-tag and GST-tag, of these proteins contribute to its antigenicity. It is 
commonly known that the fusion tags play an essential role in enhancing the protein 
solubility when expression in engineering E. coli as well as facilitating purification of 
proteins93. However, it is reported that fusion tags also contribute to the immunogenicity 
of purified antigens, which supports the results in our study94. In contrast to expectation, 
existence of purification tags seems to increase the vaccine efficacy. Efforts should be 
taken to better understand the mechanism for further vaccine developments. 
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Chapter 4 -  Identification of inhibitor of Enterohemorrhagic E. 
coli (EHEC) type  secretion system effector NleB 
Introduction 
Enterohemorrhagic E. coli (EHEC) have presented great challenges to public 
health by its potential to cause gastroenteritis, hemorrhagic colitis, and hemolytic uremic 
syndrome (HUS), which may lead to renal failure. EHEC is a prototypical member of 
attaching and effacing (A/E) pathogens, which is characterized by utilization of type  
secretion system (T3SS). T3SS is a needle-like structure which enables the pathogen to 
inject the host cell directly with a variety of virulence proteins (effectors) to modulate the 
immune system. NleB, one of those effectors, is a glycosyltransferase with the ability to 
translocate N-acetyl-D-glucosamine (N-GlcNAc) to the arginine residues of its substrate 
proteins to suppress the activation of host NF-B pathway. Therefore, the identification 
of potential inhibitors of NleB are worthy of investigation as a novel therapeutic modality 
against EHEC infection. In this study, we employed a luminescence-based 
glycosyltransferase assay to quantify the enzyme activity of NleB. After optimizing the 
glycosyltransferase assay condition, an array of chemical compounds were tested to 
screen for inhibitor candidates with the criteria of significantly decreased luminescence. 
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Materials and Methods 
Protein purification 
Escherichia coli BL21 (DE3) strains expressing NleB or mutant were grown 
overnight as described15. A single colony of each expressing strains was cultured in 4 
ml Luria-Bertani (LB) broth supplemented with 50 µg/ml Kanamycin shaking at 37 °C 
overnight. 2 ml of the overnight culture was transferred to 200 ml LB medium containing 
50 µg/ml Kanamycin. Once optical density (OD) value of the culture reached 0.4~ 0.6, 1 
mM Isopropyl β-D-1-thiogalactopyranoside (IPTG; Sigma, MO) was added to into 
culture to induce protein expression for 5 h shaking at 37 °C. Cultures were collected 
and proteins were purified by using nickel-affinity chromatography. Protein 
concentrations were quantified by using the Precision Red Advanced Protein Assay 
(Cytoskeleton, Inc.). 
N-GlcNAcylation assays 
NleB proteins were soluble in His-tag purification elution buffer which was 50 mM 
NaH2PO4 pH 8.0, 600 mM NaCl, 280 mM imidazole, 10 % glycerol. The proteins were 
added into wells of a solid white 96-well plates and diluted with His-tag purification 
elution buffer. Glycosyltransferase reaction buffer (10 µl, 2.5X) supplemented with UDP-
GlcNAc was added into each well in which the final concentration of UDP-GlcNAc was 
0.2 mM. The 1X glycosyltransferase reaction buffer contains 125 mM Tris-HCl pH 7.5, 
2.5 mM DTT, 25 mM MnCl2. The glycosyltransferase assay was performed in a total 
volume of 25 µl and incubated for 4 h at room temperature. 
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Luminescence assays 
The Luminescence assays were performed according to the protocol from 
Promega UDP-GloTM glycosyltransferase assay. Briefly, 25 µl of UDP detection reagent 
was added into glycosyltransferase reaction in each well of solid white 96 well plates. A 
UDP standard curve was performed in the same assay plate to correlate luminescence 
to the UDP concentrations generated in each glycosyltransferase reaction. UDP serial 
dilutions were diluted with glycosyltransferase reaction buffer in duplicates, and 25 µl 
UDP serial dilutions were transferred into the standard curve-designated wells of the 96-
well assay plate. 25 µl of UDP detection reagent was added and mixed thoroughly. The 
assay plates were incubated at room temperature for 1 h. Luminescence was measured 
and recorded using a luminometer. Luminescence assays were performed in triplicate 
using proteins from three independently purifications. 
Validation screening for NleB inhibitor 
The small molecule compound library screen for NleB inhibitor was performed by HTS 
lab in University of Kansas with diversity set containing 5,160 compounds synthesized 
by the Chemical Methodologies and Library Development Center. NleB (150 nM) and 
each compound (20 µM) was mixed in a 5 μl glycosyltransferase reaction buffer 
containing 0.5 % DMSO in wells of Corning® 384 Well Low Flange Black Flat Bottom 
Polystyrene NBS™ Microplate. After incubation at 30 °C for 30 min, 100 µM UDP-
GlcNAc was added to incubate at 30 °C for 2 h. UDP Detection Reagent (5 μl) in each 
well was used for detection of luminescence intensity. Luminescent readout from 
reaction without NleB is denoted as minimum signal. Luminescent readout from reaction 
without compound is denoted as maximum signal. Luminescent readout from reaction 
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with both NleB and each compound is denoted as tested signal. The inhibition 
percentage is calculated as: % Inhibition = 100 −
𝑇𝑒𝑠𝑡−𝑀𝑖𝑛
𝑀𝑎𝑥−𝑀𝑖𝑛
∗ 100. Distribution of Z’ Scores 
was employed to estimate difference among plates. Inhibition percentages of 5,160 
compounds were plotted as scattergram. Inhibition effect of compounds with scatter 
beyond plate median + 3 standard deviation were regarded as very significant. Inhibition 
effect of compounds with scatter between plate median + 2 to 3 standard deviation were 
regarded as significant. Reconfirmation of inhibition effect was performed with 
compounds at 10, 20, 40, 80, or 160 μM. Inhibition effect of compounds with scatter 
beyond plate median + 3 standard deviation and with more than 50 % max inhibition 
was regarded as very significant. 
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Results 
NleB, the T3SS effector of EHEC, plays an important role in the virulence of A/E 
pathogens by modulating the host signaling pathway. NleB functions as a 
glycosyltransferase with the ability to translocate N-acetyl-D-glucosamine (N-GlcNAc) to 
the arginine residues of its target proteins, including both mammalian proteins, such as 
GAPDH, FADD, TRADD, and NleB itself.  
In this study, we employed a luminescence-based glycosyltransferase assay to 
quantify the enzyme activity of NleB with NleB as its own substrate. We use bovine 
serum albumin (BSA) and constructed mutant NleB-AAA (NleB 221DAD-AAA223 mutant), 
which failed to N- GlcNAcylate proteins, as controls. After optimizing the conditions for 
glycosyltransferase reactions, different amount of NleB, NleB-AAA, and BSA were 
incubated with UDP-GlcNAc. After translocating GlcNAc to arginine residues of NleB, 
UDP was released and transformed to ATP to generate light which was measured by a 
luminometer. As we expected, NleB exhibited a higher intensity of luminescence than 
NleB-AAA mutant and BSA (Fig. 9). The glycosyltransferase activity increased in a 
positively linear relation with the concentration of NleB.  
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Figure 9 N-GlcNAc Transferase Activity  
 
Detection of NleB activity with UDP-Glo™ Glycosyltransferase Assay. Recombinant His-GST-
linked NleB (red) or NleB mutant (blue) or BSA (black) was added in 25 μl in glycosyltransferase 
reaction buffer in a solid white 96-well plate in the presence of 200 μM UDP-GlcNAc. After 
incubating 4 h at room temperature, the UDP-Glo™ Glycosyltransferase Assay was performed 
using 25 μl of UDP Detection Reagent. Luminescence was recorded 1 h after adding the UDP 
Detection Reagent using a 96 Microplate Luminometer. Values represent the mean of three 
replicates. RLU = relative light units. 
 
Then the reaction was applied in a 384 well plates to screen potential inhibitors 
with diversity set containing 5,160 compounds, which was performed by HTS lab in 
University of Kansas. A variety of chemical compound (5,160) were incubated with NleB 
before reaction with UDP-GlcNAc. Percentage of inhibition were calculated and 
analyzed for valid screening. Distribution of Z’ Scores (average Z’ Score: 0.88 ± 0.048) 
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showed that there was no significant difference among plates, suggesting that all plates 
were equally treated.  
The scattergram revealed that 52 hits were beyond the plate median + 3 
standard deviation of inhibition percentage and 76 hits were in plate median + between 
2 and 3 standard deviation, which means these 128 chemical compounds could be 
inhibitor candidates (Fig. 10).  
 
Figure 100 Scattergram of percent inhibition 
 
Scattergram of percent inhibition of 5,160 chemicals. Dashed lines indicate means 0 percent 
inhibition.  
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Discussion 
Type  secretion system of attaching and effacing (A/E) pathogen has raised 
increasing attention in research these years because it can manipulate host immune 
response via its versatile effectors. NleB is distinctively characterized as an N-acetyl-D-
glucosamine (N-GlcNAc) glycosyltransferase by modifying the arginine residues on 
target proteins. To execute its function, NleB is injected directly into mammalian cells 
via T3SS, which has a needle-like channel for translocation without being secreted into 
extracellular environment. This renders the advantage of evasion from immune system, 
but also leads to the predicament to target NleB for vaccine development. However, In 
the process of drug discovery, high-throughput screening is desirable and effective 
strategy to screen an inhibitor of certain virulence with a chemical or compound library. 
Chemicals or compounds in library are usually designed and synthesized by organic 
chemistry and medicinal chemistry. A systematic database is constructed to store the 
corresponding information of each chemical, including the chemical structure, purity, 
quantity, and physiochemical characteristics of the compound. In this study, we 
establish a stable reaction condition for high-throughput screening using a compound 
library of 5,160 chemicals. In total, 128 chemicals were selected with significant 
inhibition on glycosyltransferase activity of NleB and might be developed into a drug. All 
5,160 chemicals from the diversity set in this study are safe to human cell lines and able 
to permeate the cell membrane. Subsequent investigations are needed involving 
determination of IC50s, chemical kinetics, and type of inhibition. However, a potential 
drawback also exists, as there are multiple glycosyltransferases with important function 
in host cells. For instance, O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) 
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in human catalyzes intracellular glycosylation of serine and threonine residues with the 
addition of a single N-acetylglucosamine in O-glycosidic linkage. OGT plays critical 
important role in regulation of host biological function involving the resistance of insulin 
in muscle cells and adipocytes95. Therefore, the selected chemical for further therapy 
development should be tested the impacts on glycosyltransferases of host cells before 
clinical trial. In addition, NleB is characterized as highly conserved among A/E 
pathogens. Therefore, whether a global inhibiting effect exists for NleB orthologs is 
worthy of investigation in the future. In conclusion, we employed a luminescence-based 
glycosyltransferase assay using an array of chemical compounds. A total of 128 
chemicals was screened out with significant inhibiting effects on NleB to be further 
studied as a novel therapeutic modality against EHEC infection. 
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